Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells

Prostate

Volumn 68, Issue 11, 2008, Pages 1232-1240

  Ryan, Charles J ^a,b   Zavodovskaya, Marianna ^a,b   Youngren, Jack F ^a,b   Campbell, Michael ^a   Diamond, Marc ^a   Jones, Jeremy ^a   Shiry, Laura ^c   Allan, Geoffrey ^c   Maddux, Betty A ^a,b   Goldfine, Ira D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Insmed Incorporated   (United States)

Author keywords

Gene expression; Insulin like growth factor 1; Insulin like growth factor 1 receptor; NDGA; Prostate cancer; Tyrosine kinase

Indexed keywords

ANDROGEN RECEPTOR; LIGAND; MESSENGER RNA; NORDIHYDROGUAIARETIC ACID; SOMATOMEDIN C RECEPTOR;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN EXPRESSION; TISSUE CULTURE; WESTERN BLOTTING;

ANTIOXIDANTS; CELL DIVISION; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NORDIHYDROGUAIARETIC ACID; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN CONFORMATION; RECEPTOR, IGF TYPE 1; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 48749104761     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20789     Document Type: Article

References (29)

1. Nieto M, Finn S, Loda M, Hahn WC. Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol 2007;39(9):1562-1568.
2. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23(32): 8253-8261.
3. Baserga R. The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 1995;55(2):249-252.
4. Burfeind P, Chernicky CL, Rininsland F, Ilan J. Antisense, RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996;93(14):7263-7268.
5. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001;61(16):6276-6280.
6. Pollak M. Insulin-like growth factors and prostate cancer. Epidemiol Rev 2001;23(1):59-66.
7. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195(2):127-137.
8. Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 1995;73(3):311-331.
9. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6(1): 1-12.
10. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92(18):1472-1489.
11. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279(5350):563-566.
12. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998;90(12):911-915.
13. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21(3):215-244.
14. Roberts CT Jr. Insulin-like growth factor I receptor regulation in prostate carcinoma. Growth Horm IGF Res 2000;10: (Suppl A): S20-S21.
15. Waller C, Gisvold O. Phytochemical investigation of Larrea divaricata. J Am Pharm Assoc 1945;34:78-86.
16. Blecha JE, Anderson MO, Chow JM, Guevarra CC, Pender C, Penaranda C, Zavodovskaya M, Youngren JF, Berkman CE. Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs. Bioorg Med Chem Lett 2007;17(14): 4026-4029.
17. Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat 2005;94(1):37-46.
18. Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J Cell Biochem 2008;103(2):624-635.
19. Meyer GE, Chesler L, Liu D, Gable K, Maddux BA, Goldenberg DD, Youngren JF, Goldfine ID, Weiss WA, Matthay KK, Rosenthal SM. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. J Cell Biochem 2007;102(6):1529-1541.
20. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, Small EJ, Goldfine ID. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol 2007;25(2):134-140.
21. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5(3):280-285.
22. Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, deGregorio F, Elshimali YI, Heber D, Aronson WJ. Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis. Clin Cancer Res 2003;9(7):2734-2743.
23. Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, Miner JN, Diamond MI. The structural basis of androgen receptor activation: Intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci USA 2005;102(28):9802-9807.
24. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5(3):231-239.
25. Girnita A, Girnita L, del PF, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004;64(1): 236-242.
26. Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, Belfiore A. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 2005;65(5): 1849-1857.
27. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, Fukamizu A, Kato S, Takayanagi R, Nawata H. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 2007;282(10):7329-7338.
28. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate SR. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11(8):3065-3074.
29. Ryan CJ, Harzstark AH, Youngren JF, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner J, Small EJ. A pilot dose-escalation study of the effects of nordihydroguaiaretic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int 2008;101(4):436-439.